<DOC>
	<DOCNO>NCT01390415</DOCNO>
	<brief_summary>This study evaluate whether losartan protects kidney hypertensive Type II diabetic participant microalbuminuria .</brief_summary>
	<brief_title>A Study Evaluate Whether Losartan Protects Kidney Hypertensive Diabetic Participants With Microalbuminuria ( MK0954-365 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Diabetes mellitus Hypertension receive losartan 50 mg losartan 100 mg least 6 month Microalbuminuria ( define microalbuminuria &gt; 30 mg/g &lt; 300 mg/g spot urine test ) Serum creatinine ≤1.5 mg/dL men ≤1.4mg/dL woman Urinalysis white blood cell ( WBC ) &lt; 5 cell per high power field Results hemoglobin A1c ( HbA1c ) , fast blood glucose , serum creatinine , urine albumin/urine creatinine ratio urinary analysis test baseline 6 month initiate losartan therapy available Medical history comorbidities ( available ) list medical record Prescription information antihypertensive regimen losartan 50 mg 100 mg available Exclusion criterion : Treated angiotensinconverting enzyme ( ACE ) inhibitor angiotensinreceptor blocker ( ARB ) initiate treatment losartan 50 mg losartan 100 mg Enrollment another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>